These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25692079)

  • 21. A retrospective look at dysplastic nevi. What were they in 1978 and how have they fared since?
    Cockerell CJ; Berson DS
    Am J Dermatopathol; 1985; 7 Suppl():93-7. PubMed ID: 3940095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysplastic nevus part II: Dysplastic nevi: Molecular/genetic profiles and management.
    Spaccarelli N; Drozdowski R; Peters MS; Grant-Kels JM
    J Am Acad Dermatol; 2023 Jan; 88(1):13-20. PubMed ID: 36252690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Common acquired melanocytic nevi, melanocytic dysplasia and malignant melanoma. A morphometric study.
    Santucci M; Urso C; Giannini A; Bondi R
    Appl Pathol; 1989; 7(2):111-5. PubMed ID: 2730799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers.
    Quiohilag K; Caie P; Oniscu A; Brenn T; Harrison D
    Virchows Arch; 2020 Jul; 477(1):121-130. PubMed ID: 32388720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management.
    Ronen S; Al-Rohil RN; Keiser E; Jour G; Nagarajan P; Tetzlaff MT; Curry JL; Ivan D; Middleton LP; Torres-Cabala CA; Gershenwald JE; Aung PP; Prieto VG
    Arch Pathol Lab Med; 2021 Dec; 145(12):1505-1515. PubMed ID: 33577643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma.
    Smoller BR; McNutt NS; Hsu A
    Am J Surg Pathol; 1989 Aug; 13(8):680-4. PubMed ID: 2473661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysplastic nevus: why this term should be abandoned in dermatoscopy.
    Kittler H; Tschandl P
    Dermatol Clin; 2013 Oct; 31(4):579-88, viii. PubMed ID: 24075546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dysplastic nevus].
    Shchetinina LN; Parshiikova SM
    Arkh Patol; 1992; 54(2):45-7. PubMed ID: 1524502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melanocytic lesions in a private pathology practice. Comparison of histologic features in different tumor types with particular reference to dysplastic nevi.
    Hastrup N; Hou-Jensen K
    APMIS; 1993 Nov; 101(11):845-50. PubMed ID: 8286092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity and microsatellite instability in acquired melanocytic nevi: towards a molecular definition of the dysplastic nevus.
    Rübben A; Bogdan I; Grussendorf-Conen EI; Burg G; Böni R
    Recent Results Cancer Res; 2002; 160():100-10. PubMed ID: 12079204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen and progesterone receptors in melanocytic lesions. Occurrence in patients with dysplastic nevus syndrome.
    Ellis DL; Wheeland RG; Solomon H
    Arch Dermatol; 1985 Oct; 121(10):1282-5. PubMed ID: 4037821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical diagnosis of dysplastic melanocytic nevi. A clinicopathologic correlation.
    Kelly JW; Crutcher WA; Sagebiel RW
    J Am Acad Dermatol; 1986 Jun; 14(6):1044-52. PubMed ID: 3722481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysplastic melanocytic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives.
    Albert LS; Rhodes AR; Sober AJ
    J Am Acad Dermatol; 1990 Jan; 22(1):69-75. PubMed ID: 2298967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nevomelanocytic atypia detection by in vivo reflectance confocal microscopy.
    Vaišnorienė I; Rotomskis R; Kulvietis V; Eidukevičius R; Zalgevičienė V; Laurinavičienė A; Venius J; Didžiapetrienė J
    Medicina (Kaunas); 2014; 50(4):209-15. PubMed ID: 25458957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HMB-45 staining of dysplastic melanocytic nevi in melanoma risk groups.
    Ahmed I; Piepkorn M; Goldgar DE; Cannon-Albright LA; Meyer LJ; Skolnick MH; Zone JJ
    J Cutan Pathol; 1991 Aug; 18(4):257-60. PubMed ID: 1939784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
    Gao L; van den Hurk K; Moerkerk PTM; Goeman JJ; Beck S; Gruis NA; van den Oord JJ; Winnepenninckx VJ; van Engeland M; van Doorn R
    J Invest Dermatol; 2014 Dec; 134(12):2957-2966. PubMed ID: 24999589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms?
    Zembowicz A; Scolyer RA
    Arch Pathol Lab Med; 2011 Mar; 135(3):300-6. PubMed ID: 21366452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TERT Promoter Mutational Analysis as an Ancillary Diagnostic Tool for Diagnostically Challenging Melanocytic Neoplasms.
    Boutko A; Asadbeigi S; Roth A; Lampley N; Olivares S; Dittmann D; Dittmann D; Jennings L; Gerami P
    Am J Dermatopathol; 2023 May; 45(5):289-299. PubMed ID: 36898007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
    Melamed RD; Aydin IT; Rajan GS; Phelps R; Silvers DN; Emmett KJ; Brunner G; Rabadan R; Celebi JT
    J Invest Dermatol; 2017 Apr; 137(4):905-909. PubMed ID: 27890785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of molecular morphology techniques on the expert diagnosis in melanocytic skin neoplasms.
    Ferrara G; Misciali C; Brenn T; Cerroni L; Kazakov DW; Perasole A; Russo R; Ricci R; Crisman G; Fanti PA; Passarini B; Patrizi A
    Int J Surg Pathol; 2013 Oct; 21(5):483-92. PubMed ID: 23775023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.